Guy Bormans Selected Research

Guanosine Monophosphate (5' Guanylic Acid)

12/2017	Carbon-11 and Fluorine-18 Radiolabeled Pyridopyrazinone Derivatives for Positron Emission Tomography (PET) Imaging of Phosphodiesterase-5 (PDE5).
2/2014	Evaluation of PET radioligands for in vivo visualization of phosphodiesterase 5 (PDE5).
1/2014	PET imaging shows loss of striatal PDE10A in patients with Huntington disease.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Guy Bormans Research Topics

Disease

30	Neoplasms (Cancer) 03/2024 - 03/2006
13	Alzheimer Disease (Alzheimer's Disease) 12/2022 - 03/2009
11	Neuroinflammatory Diseases 01/2020 - 01/2014
11	Necrosis 01/2020 - 08/2005
11	Parkinson Disease (Parkinson's Disease) 10/2019 - 11/2006
7	Schizophrenia (Dementia Praecox) 01/2017 - 01/2013
6	Huntington Disease (Huntington's Disease) 12/2022 - 09/2010
6	Pain (Aches) 01/2018 - 04/2010
5	Inflammation (Inflammations) 10/2019 - 03/2007
4	Central Nervous System Diseases (CNS Diseases) 12/2023 - 07/2011
4	Neuroendocrine Tumors (Neuroendocrine Tumor) 06/2023 - 01/2020
4	Alcoholism (Alcohol Abuse) 01/2022 - 02/2014
4	Cognitive Dysfunction 01/2022 - 08/2007
3	Melanoma (Melanoma, Malignant) 01/2023 - 01/2019
3	Prostatic Neoplasms (Prostate Cancer) 01/2023 - 08/2012
3	Neurodegenerative Diseases (Neurodegenerative Disease) 01/2022 - 09/2019
3	Hepatocellular Carcinoma (Hepatoma) 01/2021 - 08/2017
3	Primary Progressive Aphasia 01/2020 - 01/2017
3	Rhabdomyosarcoma 01/2020 - 02/2009
3	Tauopathies 01/2020 - 06/2015
3	Anorexia Nervosa 02/2014 - 03/2007
3	Obesity 01/2014 - 01/2008
3	Neurogenic Inflammation 11/2013 - 01/2013
3	Hepatic Infarction 01/2011 - 11/2007
3	Infarction (Infarctions) 01/2008 - 01/2006
3	Myocardial Infarction 01/2008 - 08/2005
2	Leukemia 03/2024 - 01/2020
2	Mental Disorders (Mental Disorder) 01/2022 - 05/2010
2	Neoplasm Metastasis (Metastasis) 04/2021 - 01/2020
2	Atrophy 01/2018 - 01/2017
2	Pulmonary Arterial Hypertension 12/2017 - 02/2014
2	Amyloidosis 11/2016 - 08/2009
2	Anorexia 02/2014 - 10/2011
2	Feeding and Eating Disorders (Eating Disorder) 02/2014 - 10/2011
2	Hypersensitivity (Allergy) 07/2010 - 05/2007
1	Multiple Myeloma 03/2024
1	Glioblastoma (Glioblastoma Multiforme) 01/2023
1	Ischemia 01/2023
1	Neuroblastoma 01/2023
1	Paraganglioma (Paragangliomas) 01/2023

Drug/Important Bio-Agent (IBA)

12	Cannabinoid Receptors (Cannabinoid Receptor)IBA 01/2022 - 06/2008
10	EndocannabinoidsIBA 12/2023 - 03/2008
6	Proteins (Proteins, Gene)FDA Link 12/2022 - 01/2014
6	Phosphoric Diester Hydrolases (Phosphodiesterases)IBA 01/2022 - 01/2013
6	Biomarkers (Surrogate Marker)IBA 10/2021 - 08/2009
6	LigandsIBA 09/2020 - 04/2007
6	Ethanol (Ethyl Alcohol)IBA 02/2014 - 07/2007
6	hypericinIBA 12/2012 - 12/2003
5	1,4,7- triazacyclononane- N,N',N''- triacetic acid (NOTA)IBA 03/2024 - 01/2020
5	Radioisotopes (Radionuclides)IBA 04/2021 - 07/2010
5	Purinergic P2X7 ReceptorsIBA 01/2020 - 01/2016
5	Amyloid (Amyloid Fibrils)IBA 01/2020 - 08/2007
5	N,N- diethyl- 2- (2- (4- (2- fluoroethoxy)phenyl)- 5,7- dimethylpyrazolo(1,5- a)pyrimidin- 3- yl)acetamideIBA 10/2019 - 10/2015
5	CannabinoidsIBA 01/2019 - 01/2008
5	CB1 Cannabinoid Receptor (CB1 Receptor)IBA 02/2014 - 02/2010
4	Somatostatin Receptors (Somatostatin Receptor)IBA 03/2023 - 01/2018
4	fosbretabulin (combretastatin A4)IBA 01/2020 - 09/2011
4	salicylhydroxamic acid (SHAM)IBA 11/2012 - 05/2007
3	Octreotide (Sandostatin)FDA LinkGeneric 06/2023 - 01/2020
3	Somatostatin (Somatotropin Release-Inhibiting Factor)IBA 01/2023 - 01/2018
3	Amyloid beta-PeptidesIBA 01/2022 - 03/2009
3	EnzymesIBA 01/2022 - 01/2013
3	Metabotropic Glutamate 5 ReceptorIBA 01/2020 - 12/2015
3	Contrast MediaIBA 01/2020 - 08/2005
3	LipopolysaccharidesIBA 12/2018 - 10/2015
3	Guanosine Monophosphate (5' Guanylic Acid)IBA 12/2017 - 01/2014
3	SolutionsIBA 10/2015 - 03/2006
3	Pentetic Acid (DTPA)FDA LinkGeneric 06/2013 - 11/2007
3	Oxidopamine (6 Hydroxydopamine)IBA 02/2010 - 11/2006
2	plerixafor FDA Link 03/2024 - 10/2021
2	68Ga-pentixaforIBA 03/2024 - 10/2021
2	6- amino- 8- ((6- iodo- 1,3- benzodioxol- 5- yl)thio)- N- (1- methylethyl)- 9H-purine-9-propanamineIBA 01/2023 - 01/2019
2	tau Proteins (tau Protein)IBA 01/2023 - 01/2019
2	7- (6- fluoropyridin- 3- yl)- 5H- pyrido(4,3- b)indoleIBA 01/2022 - 01/2020
2	Therapeutic UsesIBA 01/2021 - 10/2015
2	Vascular Endothelial Growth Factor Receptor-2 (Vascular Endothelial Growth Factor Receptor 2)IBA 01/2021 - 11/2016
2	Gallium-68IBA 01/2020 - 07/2010
2	Levodopa (L Dopa)FDA LinkGeneric 10/2019 - 03/2012
2	Phosphates (Orthophosphate)IBA 07/2018 - 08/2017
2	Dihydrotachysterol (AT 10)IBA 07/2018 - 08/2017
2	Type 5 Cyclic Nucleotide PhosphodiesterasesIBA 12/2017 - 02/2014
2	2- oxo- 7- methoxy- 8- butyloxy- 1,2- dihydroquinoline- 3- carboxylic acid cyclohexylamideIBA 11/2016 - 08/2013
2	CationsIBA 04/2013 - 01/2013
2	IodineIBA 07/2012 - 09/2011
2	pamoic acidIBA 07/2010 - 11/2007
2	Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link 03/2007 - 01/2005
1	CXC ChemokinesIBA 03/2024
1	RadiopharmaceuticalsIBA 08/2023
1	(2,4- dihydroxy- 5- isopropylphenyl)- (5- (4- methylpiperazin- 1- ylmethyl)- 1,3- dihydroisoindol- 2- yl)methanoneIBA 01/2023
1	AntigensIBA 01/2023
1	18F-JK-PSMA-7IBA 01/2023
1	3-Iodobenzylguanidine (Iobenguane)IBA 01/2023
1	Muscarinic M4 ReceptorIBA 12/2022
1	Dopamine (Intropin)FDA LinkGeneric 01/2022
1	Apolipoproteins E (ApoE)IBA 01/2022

Therapy/Procedure

14	Therapeutics 08/2023 - 01/2005
5	Drug Therapy (Chemotherapy) 01/2020 - 07/2003
3	Aftercare (After-Treatment) 01/2020 - 03/2007
2	Prostatectomy (Retropubic Prostatectomy) 01/2023 - 08/2012
2	Gastric Balloon 10/2013 - 05/2007